Inhibition of Group IVA Cytosolic Phospholipase A2by Novel 2-Oxoamides in Vitro, in Cells, and in Vivo
Citations Over TimeTop 15% of 2004 papers
Abstract
The Group IVA cytosolic phospholipase A(2) (GIVA PLA(2)) is a particularly attractive target for drug development because it is the rate-limiting provider of proinflammatory mediators. We previously reported the discovery of novel 2-oxoamides that inhibit GIVA PLA(2) [Kokotos, G.; et al. J. Med. Chem. 2002, 45, 2891-2893]. In the present work, we have further explored this class of inhibitors and found that the 2-oxoamide functionality is more potent when it contains a long 2-oxoacyl residue and a free carboxy group. Long-chain 2-oxoamides based on gamma-aminobutyric acid and gamma-norleucine are potent inhibitors of GIVA PLA(2). Such inhibitors act through a fast and reversible mode of inhibition in vitro, are able to block the production of arachidonic acid and prostaglandin E(2) in cells, and demonstrate potent in vivo anti-inflammatory and analgesic activity.
Related Papers
- → Different Influences of trans Fatty Acids on the Phospholipase A2 and Arachidonic Acid Metabolic Pathway in Hepatocytes(2021)16 cited
- → Accumulation of arachidonic acid in ischemic/reperfused cardiac tissue: possible causes and consequences(1997)78 cited
- → Reduced tumour necrosis factor-induced cytotoxicity by inhibitors of the arachidonic acid metabolism(1987)122 cited
- → Effect of ethanol on platelet phospholipase A2(1992)41 cited
- → Platelet Activation by Tetraprenol via Stimulation of Phospholipase A2 Action(1989)5 cited